Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities
- 1University of Colorado School of Medicine
Abstract
Objective: To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report. Methods: Using a large language model validated against physician review, we analyzed 92,254 posts and comments from 28,652 users in Reddit's peptide communities from 2021 to 2026. We compared side effects with those reported by users of four other peptides in the same communities. Results: In all, 5,588 users described using BPC-157 and/or TB-500 for a specific musculoskeletal injury, most often a chronic tendon problem of the shoulder, knee or elbow. Only 3.8% of users described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors. The median BPC-157 dose (366 mcg per injection) was about 2.7 times the human-equivalent dose of the 10 mcg/kg rat regimen, and among new users it rose from 300 mcg in 2024 to 500 mcg in 2025. Of those stating an outcome, 79.3% reported improvement, and 36.6% of all users were also in physical therapy. Overall, 27.2% described at least one side effect, most often fatigue, anxiety, anhedonia and insomnia. Anhedonia was more common than among users of the four other peptides (10.2% versus 1.3% of those with side effects). Conclusion: Use of these unapproved peptides for musculoskeletal injury is largely unsupervised, relying on grey-market products at self-selected, rising doses without established safety or efficacy.
Related
- Musculoskeletal Symptoms Among Agricultural Workers in Rural Communities of Loja, Ecuador
- A recommendation model based on profile enhancement for personalized medical expert in online health communities
- 'I love my AI girlfriend': a content analysis of youth social AI risk in online communities
- Successful Treatment of Varicella Zoster Encephalitis in a Sarcopenic Obese Patient after Acyclovir-induced Acute Kidney Injury: The Necessity of Individualized Dosing
- Use of patient-reported outcome measures for upper limb musculoskeletal conditions among physiotherapists in Tamil Nadu, India: a mixed-methods study
BibTeX
@misc{cassinat2026realworld,
title = {{Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities}},
author = {J. J. Cassinat and C. Callan and C. Liggett and V. Wright},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.04.26367022},
url = {https://www.medrxiv.org/content/10.64898/2026.11.04.26367022v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities
AU - J. J. Cassinat
AU - C. Callan
AU - C. Liggett
AU - V. Wright
PY - 2026
DA - 2026/11/04
PB - medRxiv
DO - 10.64898/2026.11.04.26367022
UR - https://www.medrxiv.org/content/10.64898/2026.11.04.26367022v1
AB - Objective: To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report. Methods: Using a large language model validated against physician review, we analyzed 92,254 posts and comments from 28,652 users in Reddit's peptide communities from 2021 to 2026. We compared side effects with those reported by users of four other peptides in the same communities. Results: In all, 5,588 users described using BPC-157 and/or TB-500 for a specific musculoskeletal injury, most often a chronic tendon problem of the shoulder, knee or elbow. Only 3.8% of users described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors. The median BPC-157 dose (366 mcg per injection) was about 2.7 times the human-equivalent dose of the 10 mcg/kg rat regimen, and among new users it rose from 300 mcg in 2024 to 500 mcg in 2025. Of those stating an outcome, 79.3% reported improvement, and 36.6% of all users were also in physical therapy. Overall, 27.2% described at least one side effect, most often fatigue, anxiety, anhedonia and insomnia. Anhedonia was more common than among users of the four other peptides (10.2% versus 1.3% of those with side effects). Conclusion: Use of these unapproved peptides for musculoskeletal injury is largely unsupervised, relying on grey-market products at self-selected, rising doses without established safety or efficacy.
ER -